Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RB1 |
Variant | G449R |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | RB1 G449R lies within domain A of the Rb1 protein (UniProt.org). G449R has been identified in sequencing studies (PMID: 26373574, PMID: 30578357, PMID: 24688104), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, May 2024). |
Associated Drug Resistance | |
Category Variants Paths |
RB1 mutant RB1 G449R |
Transcript | NM_000321.3 |
gDNA | chr13:g.48379606G>A |
cDNA | c.1345G>A |
Protein | p.G449R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000321.2 | chr13:g.48379606G>A | c.1345G>A | p.G449R | RefSeq | GRCh38/hg38 |
NM_001407165.1 | chr13:g.48379606G>A | c.1345G>A | p.G449R | RefSeq | GRCh38/hg38 |
NM_001407166.1 | chr13:g.48379606G>A | c.1345G>A | p.G449R | RefSeq | GRCh38/hg38 |
NM_000321 | chr13:g.48379606G>A | c.1345G>A | p.G449R | RefSeq | GRCh38/hg38 |
NM_000321.3 | chr13:g.48379606G>A | c.1345G>A | p.G449R | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 mutant | estrogen-receptor positive breast cancer | predicted - resistant | Palbociclib | Phase III | Actionable | In a Phase III trial (PALOMA-3), acquired RB1 mutations were identified in patents with ER-positive, ERBB2 (HER2)-negative breast cancer at the end of treatment in the Faslodex (fulvestrant) plus Ibrance (palbociclib) but not the Faslodex (fulvestrant) plus placebo arm, suggesting a role in conferring resistance to Ibrance (palbociclib) (PMID: 30206110; NCT01942135). | 30206110 |
RB1 mutant | osteosarcoma | sensitive | VCN-01 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261). | 26603261 |